Ahead Of Speech, Democrats Skeptical About Trump Drug Pricing Plans
Executive Summary
US House members and Center for American Progress urge policies that directly target drug pricing practices and not only patient cost sharing.
You may also be interested in...
A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?
US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.
Clinton’s Drug Plan Embraces CER-Driven Pricing ‘Accountability’
Think tank report that informed the plan suggests impact of CER reviews could be bolstered by use of NIH "march-in" rights if prices stay "unreasonably" high despite review conclusions.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.